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Purpose. To examine the efficacy of ophthalmic rebamipide suspensions on ocular surface disorders induced by antiglaucoma
eye drops. Patients and Methods. Forty eyes of 40 patients receiving latanoprost (0.005%) and timolol (0.5%) were included in
this randomized prospective study. The patients were randomly divided into two groups (n = 20): the rebamipide-treated group
and control group. Changes in intraocular pressure, tear film break-up time (TBUT), and corneal epithelial barrier function were
evaluated at baseline, 4 weeks, and 8 weeks after rebamipide administration. Furthermore, superficial punctate keratopathy severity
was evaluated by scoring the lesion area and density. Results. There was no significant difference in intraocular pressure before and
after rebamipide treatment. However, corneal epithelial barrier function improved significantly 4 and 8 weeks after rebamipide
treatment. TBUT was partially, but significantly, increased (P = 0.02) 8 weeks after rebamipide treatment, whereas no significant
change was observed at 4 weeks. Additionally, a significant decrease in area and density of keratopathy was observed 8 weeks after
rebamipide treatment but not at 4 weeks. The control group showed no significant difference compared to baseline. Conclusions.
Our data suggests that rebamipide treatment may reduce the occurrence of drug-induced ocular surface disorder.
1. Introduction
Ocular surface diseases occur in 15% of elderly patients and
48–59% of patients with glaucoma [1–3]. Ocular surface
disease is hypothesized to occur in patients with glaucoma
due to the side effects of antiglaucoma eye drops or glau-
coma surgery. Antiglaucoma eye drops are associated with
a decrease in lacrimal fluid and disturbances in corneal
epithelial barrier function [4]. When drug-induced corneal
disorders occur, the use of antiglaucoma eye drops is gener-
ally stopped; however, this can lead to intraocular pressure
elevation. Thus, it would be preferable to improve drug-
induced corneal disorders without discontinuing the use of
antiglaucoma eye drops.
Ophthalmic rebamipide suspensions are approved ther-
apeutic agents for dry eye in Japan. After systemic oral
intake, rebamipide increasesmucin secretion from the gastric
mucus, and it has been used clinically to treat gastritis and
gastric ulcers [5–7]. Because of its effects on gastric mucin
secretion, it was hypothesized that rebamipidemight enhance
mucin production in conjunctival goblet cells. Indeed, previ-
ous studies indicate that mucin production in conjunctival
goblet cells was increased after rebamipide treatment [8, 9].
Given that dry eye is caused by decreased mucin levels on
the ocular surface and impaired stabilization of the aqueous
layer [10], rebamipide was developed as a treatment for dry
eye. Although a recent study demonstrated that rebamipide
ophthalmic suspensions were effective in treating keratocon-
junctivitis sicca in patients with Sjögren’s syndrome [11], its
effect on the ocular surface condition in glaucoma patients
who are using antiglaucoma eye drops remains unclear.
The purpose of this randomized and prospective study
was to examine the effect of rebamipide eye drops to prevent
antiglaucoma eye drop-induced corneal disorders.
2. Materials and Methods
Forty eyes of 40 glaucoma patients (mean age: 62.8 ± 13.1
years) were used uponmeeting the diagnostic criteria for dry
eye [12].The inclusion criteria for participating in the present
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study were as follows: history of treatment with 0.005%
latanoprost containing benzalkonium chloride (BAK) and
0.5% timolol containing BAK (unfixed combination) for six
or more months, fluorescein staining score of 2 or more
points, and symptoms, such as eye discomfort. The eyes were
randomized into two groups: 20 eyes of 20 patients (mean
age 61.4 ± 14.2 years; 8 men, 12 women) received ophthalmic
suspensions containing rebamipide, while 20 eyes of 20
patients (mean age 64.3±12.1 years; 13men, 7women) did not
receive rebamipide (control). For the rebamipide treatment
group, the subjects received rebamipide eye drops four times
per day every day during the observation period.
Intraocular pressure (IOP) was measured by a single
examiner (NT) throughout the examination period with a
Goldmann applanation tonometry at 11:00 am in a sitting
position.
To evaluate corneal epithelial barrier function, a slit
lamp fluorophotometer for the anterior eye was used (Kowa,
FL-500, Tokyo, Japan). According to the method by Yokoi
and Kinoshita [13], the background fluorescence intensity
of the central cornea was measured. Using a micropipette,
0.5% fluorescein sodium solution dissolved in BSS PLUS
(3 𝜇L, Alcon, Fort Worth, TX, USA) was applied to the
lower conjunctival sac without contact. Eyes were washed
with BSS PLUS (20mL) 10min after application. Fluorescein
uptake was measured 30min after application using the same
protocol used in the baseline measurement. The background
was subtracted, and the fluorescein uptake concentration was
calculated based on a standard curve as a built-in function of
the FL-500.The data were expressed as ng/mL (normal value:
28±16 ng/mL). For example, over 50 ng/mL indicates corneal
epithelial barrier dysfunction [14].
Slit lamp microscopy was used to measure corneal status
and tear film break-up time (TBUT) [15]. To measure TBUT,
fluorescein sodium was applied to the eye, and the patient
blinked several times to allow for uniform distribution. The
time until dry spots occurred in the cornea of the open
eye was measured three times, and the mean was used. The
severity of superficial punctate keratopathy was evaluated by
area-density (AD) classification [16], which scores the range
of the lesion (area) and the density of the spotted stain.
Data were analyzed using IBM SPSS Statistics 21 (IBM
Corporation, Poughkeepsie, NY, USA). Each examination
was analyzed using a paired 𝑡-test, and a 𝑃 value less than
0.05 was considered statistically significant. This study was
performed after the approval of the ethical committee of our
hospital (ethical committee approval number: 1933), and all
the patients provided written informed consent.
3. Results
We first assessed changes in intraocular pressure in patients
undergoing control or rebamipide treatment (Figure 1).
Rebamipide treatment had no effect on the intraocular
pressure in patients receiving antiglaucoma eye drops (16.6 ±
2.3mmHg at baseline; 15.8 ± 2.3mmHg after 4 weeks; and
15.6 ± 1.8mmHg after 8 weeks). Furthermore, no changes
in pressure were observed in the eyes of control glaucoma


























Figure 1: Changes in intraocular pressure in the rebamipide-
treated group and control group. Both groups maintained reduced
intraocular pressure without significant difference during follow-up.
weeks; and 15.9±2.2mmHg after 8 weeks). Importantly, both
groups maintained reduced intraocular pressure without
significant difference during follow-up.
We next assessed the corneal epithelial barrier function
in glaucoma patients receiving control or rebamipide treat-
ment (Figure 2). Notably, substantial increases in fluorescein
uptake were observed in both groups at baseline, since both
groups received 0.005% latanoprost containing BAK and
0.5% timolol containing BAK, indicating the existence of
corneal epithelial barrier dysfunction induced by antiglau-
coma drops. In contrast, significant decreases in fluorescein
uptake were observed in eyes treated with rebamipide after 4
and 8weeks (120.7±56.1 ng/mL at baseline; 87.7±43.8 ng/mL
after 4 weeks [𝑃 = 0.012]; and 91.5 ± 37.9 ng/mL after 8
weeks [𝑃 = 0.017]). In contrast, no significant difference
in fluorescein uptake was observed in control eyes (119.9 ±
61.7 ng/mL at baseline; 123.6±44.4 ng/mL after 4 weeks [𝑃 =
0.671]; and 119.9 ± 42.4 ng/mL after 8 weeks [𝑃 = 0.995]).
Next, we analyzed TBUT in glaucoma patients receiving
control or rebamipide treatment (Figure 3).There was no sta-
tistical difference between the control group and rebamipide-
treated group at the baseline (5.8 ± 1.4 s and 5.2 ± 1.5 s,
resp., 𝑃 = 0.220). Treatment with rebamipide partially but
significantly increasedTBUTat 8weeks (5.2±1.5 s at baseline;
5.9 ± 1.6 s after 8 weeks, 𝑃 = 0.02), although no significant
differences were observed at 4 weeks (5.2 ± 1.5 s at baseline;
5.4 ± 0.8 s after 4 weeks, 𝑃 = 0.331). No significant difference
was observed in the control group (5.8 ± 1.4 s at baseline;
5.9 ± 0.9 s after 4 weeks, 𝑃 = 0.771; and 5.6 ± 1.0 s after 8
weeks, 𝑃 = 0.082).
Finally, we assessed superficial punctate keratopathy in
glaucoma patients by AD classification (Figure 4). Treatment
with rebamipide resulted in significant improvements in
keratopathy at 8 weeks, but there were no changes at 4 weeks
(2.1±0.7 points at baseline; 1.9±0.7 points after 4 weeks, 𝑃 =
0.162; and 0.8±1.0 points after 8 weeks,𝑃 < 0.001). However,
no significant difference was observed in the control group
(2.1 ± 0.7 points at baseline; 2.2 ± 0.4 points after 4 weeks,
𝑃 = 0.66; and 2.4 ± 0.6 points after 8 weeks, 𝑃 = 0.06).


























































Figure 2: Changes in fluorescein uptake in the rebamipide-treated
group and control group. Significant decreases in fluorescein uptake
were observed in eyes treated with rebamipide after 4 and 8 weeks





















































Figure 3: Changes in TBUT in the rebamipide-treated group and
control group. Treatment with rebamipide partially but significantly
increased TBUT at 8 weeks, although no significant differences
were observed at 4 weeks. However, no significant difference was
observed in the control group. ∗𝑃 < 0.05.
4. Discussion
Ophthalmic rebamipide suspensions are sterilized, single-
use disposable therapeutics that lack preservatives to prevent
secondary pollution. Thus, rebamipide is expected to have
a beneficial effect on the ocular surface. Therefore, we
attempted to evaluate its effect in view of several ocular
surface factors in antiglaucoma eye drops-induced corneal
disorder.
Fluorophotometry is a technique that can evaluate
corneal epithelial barrier function. In this method, enhanced
uptake of fluorescein indicates decreased corneal epithelial
barrier function. Using thismethod, previous studies demon-
strated the effects of antiglaucoma eye drops containing
preservatives, such as BAK, on corneal epithelial barrier
function [4, 13, 14, 17–19]. For example, a previous study
showed that fluorescein uptake was significantly increased

















































Figure 4: Changes in AD score in the rebamipide-treated group
and control group. Treatmentwith rebamipide resulted in significant
improvements in keratopathy at 8 weeks, but there were no changes
at 4 weeks. However, no significant difference was observed in the
control group. ∗𝑃 < 0.001.
BAK (baseline and postexposure values: 37.5 and 82.0 ng/mL,
resp., 𝑃 < 0.001 for preserved timolol, and 35.4 versus
57.6 ng/mL, resp., 𝑃 < 0.001 for unpreserved timolol), and
it also showed that preserved timolol exerted a greater effect
(𝑃 = 0.028) in healthy volunteers [14]. A different study
showed that although the difference in corneal fluorescein
uptakewas not significant, it increased from 31.3±33.0ng/mL
to 72.3±74.9 ng/mL in eyes treatedwith timolol solutionwith
BAK (𝑃 = 0.073) in healthy volunteers [18]. Since timolol
with BAK alone affects corneal epithelial barrier function
even in the healthy subjects, it is reasonable to expect that
timolol with BAK and other antiglaucoma eye drops with
BAK further decrease corneal epithelial barrier function in
glaucoma patients. Indeed, Ishibashi et al. [19] reported that
fluorescein uptake was higher when eyes were treated with
a combination of latanoprost and BAK plus 𝛽-blockers and
BAK (118.9 ± 25.9 ng/mL) than when eyes were treated with
latanoprost with BAK alone (57.1 ± 11.0 ng/mL) after 30
days. Furthermore, a report by Nakagawa et al. [20] indicated
that latanoprost prepared with or without BAK can reduce
corneal epithelial barrier function, implying that latanoprost
itself also affects barrier function. Consistent with these
findings, in the present study, we found that the group treated
with timolol maleate and latanoprost showed exceedingly
high fluorescein uptake at baseline in both the rebamipide-
treated group and the rebamipide-untreated group (120.7 ±
56.1 ng/mL and 119.9 ± 61.7 ng/mL, resp.). These findings
suggest that corneal epithelial barrier function was decreased
by latanoprost with BAK and timolol maleate with BAK.
In the present study, we found that fluorescein uptake was
significantly decreased in eyes treated with rebamipide after 4
or 8 weeks, as compared to baseline. Another group recently
demonstrated that rebamipide increases barrier function
in a human corneal epithelial cell line, as measured by
transepithelial electrical resistance [21]. Therefore, it is likely
that rebamipide can increase corneal barrier function in
vivo and in vitro. The in vitro study also demonstrated the
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anti-inflammatory effects of rebamipide because rebamipide
inhibited increases in interleukin- (IL-) 6 and IL-8 induced
by tumor necrosis factor (TNF) [21]. These data suggest that
antiglaucoma eye drop-induced corneal disorder is associ-
ated with inflammation because eyes treated with latanoprost
with BAK and timolol with BAK had a higher mean number
of inflammatory cells than eyes treated with artificial tears in
the epithelium and superficial stroma in rabbits [22].
Furthermore, TBUT is widely used as a parameter to
noninvasively evaluate the stability of the tear layer [15].
In a report by Kinoshita et al. [23], ophthalmic rebamipide
suspensions were administered in patients with dry eye,
resulting in a significant increase in TBUT versus the placebo
group. Antiglaucoma eye drop-related corneal disorders are
caused by decreased TBUT [2, 24, 25] and a reduction in
goblet cell density [26, 27]. Timolol maleate is reported
to decrease lacrimal fluid secretion through its local anes-
thetic effect [28] and through its toxic effect on the kera-
toconjunctival epithelium [29]. Both 𝛽-adrenergic receptor
blockers and prostaglandin analogs as well as reductions in
corneal sensitivity can decrease lacrimal fluid. The impact of
antiglaucoma eye drops on the cornea is great because these
drugs are administered without dilution. Repeated expo-
sure of the cornea to antiglaucoma eye drops can enhance
inflammatory cytokines, such as TNF, IL-1𝛽, IL-6, and IL-
8, thereby impairing corneal epithelial barrier function [30–
33], leading to drug-induced ocular surface disorders. In the
present study, we found that rebamipide had no effect on
intraocular pressure but it decreased fluorescein uptake and
AD score as well as enhancing TBUT. These results suggest
that ophthalmic rebamipide suspensionsmay improve ocular
surface disease as well as corneal epithelial barrier function
while allowing for the maintenance of intraocular pressure
with antiglaucoma eye drops. The limitations of the current
study include a small sample size and a relatively short follow-
up duration. Because antiglaucoma eye drops need to be
continued for long periods, the effect of rebamipide should
be evaluated for longer times.
In conclusion, these findings suggest that ophthalmic
rebamipide suspensions may improve dry eye and repair
drug-induced keratopathy when antiglaucoma eye drop-
induced ocular surface disorder occurs.
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